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Enhanced ZnR/GPR39 Activity 
in Breast Cancer, an Alternative 
Trigger of Signaling Leading to Cell 
Growth
Hila Ventura-Bixenshpaner1, Hila Asraf1, Moumita Chakraborty1, Moshe Elkabets2,  
Israel Sekler1, Kathryn M. Taylor  3 & Michal Hershfinkel  1
Acquired resistance to the estrogen receptor (ER) antagonist tamoxifen, is a major obstacle in 
treatment of breast cancer. Changes in Zn2+ accumulation and distribution are associated with 
tamoxifen-resistance and breast cancer progression. The Zn2+-sensing G-protein coupled receptor, ZnR/
GPR39, triggers signaling leading to cell growth, but a role for this receptor in breast cancer in unknown. 
Using fluorescence imaging, we found Zn2+-dependent Ca2+ release, mediated by ZnR/GPR39 activity, 
in TAMR tamoxifen-resistant cells derived from MCF-7 cells, but not in ER-expressing MCF-7 or T47D 
cells. Furthermore, ZnR/GPR39 signaling was monitored in ER negative BT20, MDA-MB-453 and JIMT-1 
cells. Expression of ZnR/GPR39 was increased in grade 3 human breast cancer biopsies compared to 
grade 2. Consistently, analysis of two breast cancer patient cohorts, GDS4057 and TCGA, indicated that 
in ER-negative tumors higher ZnR/GPR39 mRNA levels are associated with more aggressive tumors. 
Activation of ZnR/GPR39 in TAMR cells triggered MAPK, mTOR and PI3K signaling. Importantly, 
enhanced cell growth and invasiveness was observed in the ER negative breast cancer cells, TAMR, 
MDA-MB-453 and BT20 cells but not in the ER expressing MCF-7 cells. Thus, we suggest ZnR/GPR39 as 
a potential therapeutic target for combination treatment in breast cancer, particularly relevant in ER 
negative tumors.
Activation of signaling pathways and transcription by the steroid hormone estrogen, via the estrogen receptor 
(ER), regulates mammary epithelial cell growth. In breast cancer, the expression of ER is used as a biomarker to 
guide therapy, and ER positive breast cancer patients are often treated with antihormones such as tamoxifen. 
However, resistance of tumors to tamoxifen develops in the majority of treated patients, leading to recurrence and 
progression of the disease1,2. Tamoxifen resistance may occur through alteration of different signaling pathways, 
for example, upregulation of EGF, IGF and HER2 receptor tyrosine kinases may downregulate ER expression3,4. 
In addition, acquired mutations in the ER have been shown to induce endocrine resistance5,6, and early iden-
tification of these mutations can guide therapy switching6,7. Constitutive activation of intracellular signaling, 
associated with cell growth, plays an important role in cancer progression and aggressiveness, particularly prom-
inent is the PI3K/AKT pathway that is activated in 75% of breast cancers8. Indeed, inhibitors of the PI3K/AKT 
pathway are proposed as single agent drugs, or, more effectively, in combination treatment with ER inhibitors9–13. 
Revealing mechanisms that underlie acquisition of tamoxifen resistance or constitutive signaling, is essential to 
elucidating novel therapeutic approaches to breast cancer.
Zinc is an essential micronutrient, and free Zn2+ ions emerged as important cellular signaling molecules 
involved in cell growth and survival14,15. Changes in Zn2+ levels and Zn2+ homeostatic proteins are monitored in 
breast cancer cells and tissues and are associated with more invasive behavior16–20. Activation of kinase signaling 
pathways in breast cancer MCF-7 cells is mediated, for example, by the endoplasmic reticulum Zn2+ transporter 
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ZIP721,22. Increased expression of ZIP7, concomitant with endoplasmic reticulum Zn2+ accumulation, was moni-
tored in tamoxifen resistant cells derived from MCF-7 cells, termed TAMR22–24. These changes in ZIP7 expression 
were further associated with enhanced EGFR activation and breast cancer cell growth25. Furthermore, changes in 
the expression of different members of the ZIP family of Zn2+ transporters lead to epithelial to mesenchymal tran-
sition in breast cancer cells20,26–28. In normal breast tissue, Zn2+ is transported by ZnT2 into the milk-containing 
vesicles29. In breast cancer cells and tissues, downregulation of ZnT2 induces mislocalization of cellular Zn2+ 
leading to cell survival16, likely via attenuation of lysosomal cell death mechanisms30,31.
Free-Zn2+ concentrations, within the cytoplasmic region or extracellular domain, are in the femtomolar range, 
but this ion is found in high concentrations in vesicular organelles in many cell types32. The release of vesicular 
Zn2+ induces robust and transient rises in its local concentrations, followed by rapid re-uptake via ZIP transport-
ers or chelation by Zn2+ binding proteins15. Such transient changes in concentrations of extracellular Zn2+ induce 
signaling via a Zn2+-sensing, G-protein coupled receptor, ZnR/GPR3933–35. The ZnR/GPR39 triggers intracel-
lular Ca2+ release and subsequently activates the mitogen activated protein kinase (MAPK) or PI3K/AKT path-
ways36–38. Indeed, Zn2+-dependent activation of MAPK pathway in keratinocytes was mediated by ZnR/GPR39 
and induced enhanced cell growth in a scratch assay model39. Similarly, ZnR/GPR39 activation of MAPK, PI3K 
and clusterin were shown to enhance survival of colon cancer cells following treatment with apoptosis-inducing 
butyrate40,41. The ZnR/GPR39-dependent epithelial cell growth is mediated by the signaling pathways that are 
constitutive active in tamoxifen resistant breast cancer8,42. We, therefore, hypothesized that ZnR/GPR39 may be 
an upstream regulator of breast cancer cell proliferation.
Results
ZnR/GPR39 is functional in breast cancer cells. We first asked if there is Zn2+-dependent Ca2+ sig-
naling in breast cancer cell lines, initially comparing the response of MCF-7 cells (ERα, PR positive cells that 
express low levels of HER2) to that of the tamoxifen resistant TAMR cell line derived from MCF-7 cells25,43,44. 
Extracellular Zn2+ (200 μM) triggers Fura-2 responses in TAMR cells but not in MCF-7 cells, which have lower 
levels of ZnR/GPR39 mRNA (Fig. 1A,B). Application of ATP (25 µM), which activates the purinergic metabo-
tropic pathway, triggered a clear response in MCF-7 cells, indicating that the IP3 pathway and Ca2+ intracellu-
lar stores are intact in these cells (inset Fig. 1A). Dose response analysis (Fig. 1C) of the Zn2+-dependent Ca2+ 
response, indicates that TAMR cells have a Km of 19 ± 8 µM to Zn2+, while MCF-7 show only residual activ-
ity with Km of 43 ± 19 µM and maximal Ca2+ signaling activity that is 3-fold lower than that of TAMR cells. 
To determine the role of the IP3 pathway in the Zn2+-dependent Ca2+ response, intracellular Ca2+ stores were 
depleted, using the SERCA inhibitor Thapsigargin (200 nM) and ATP (25 µM). Subsequently, Zn2+ did not trigger 
a response in either TAMR or MCF-7 cells (Fig. 1D), suggesting that the Zn2+-dependent response requires intact 
intracellular Ca2+ stores. Since Fura-2 is also sensitive to Zn2+, we asked if the fluorescence response monitored 
in TAMR cells may be also triggered by Zn2+ permeation. Following depletion of the Ca2+ stores, as above, cells 
were treated with Zn2+ (200 μM) in the presence or absence of the Zn2+ ionophore, pyrithione (5 μM, Fig. 1E). 
The Fura-2 fluorescence rise was only monitored in cells treated with Zn2+ in the presence of pyrithione (Fig. 1E) 
and subsequent addition of the cell permeable Zn2+ chelator, TPEN (10 μM), lowered this signal. Similarly, cells 
loaded with the Zn2+-sensitive fluorescent dye Fluozin-3 showed increased fluorescent signal only when Zn2+ was 
applied in the presence of pyrithione (Fig. 1F), and TPEN reversed this signal. Thus, we conclude that extracellu-
lar Zn2+ triggers release of intracellular Ca2+ from thapsigargin sensitive stores in TAMR cells.
We then asked if a Gαq-dependent signaling pathway is mediating the Zn2+-dependent Ca2+ release in TAMR 
cells37,38. In the presence of the Gαq inhibitor, YM-254890 (1 μM), the Zn2+-dependent Ca2+ response was inhib-
ited (Fig. 2A,D) as well as the purinergic receptor signaling triggered by ATP (see inset). We then specifically 
addressed the role of ZnR/GPR39 in mediating the Zn2+-dependent Ca2+ response in breast cancer cells by either 
overexpression or siRNA silencing of GPR39 (siGPR39). TAMR cell transfected with the siGPR39 construct, 
exhibited lower ZnR/GPR39 mRNA level (inset, Fig. 2B) and completely lost the Zn2+-dependent Ca2+ response 
that was preserved in cells transfected with siControl (Fig. 2B,D). Silencing of GPR39 did not affect the response 
to ATP, indicating that ZnR/GPR39 is required for mediating Zn2+-dependent Ca2+ response in TAMR cells. 
Desensitization following prolonged exposure to the ligand is a hallmark of GPCRs activity, which is particularly 
prominent in ZnR/GPR3937,39. To determine whether Zn2+ induces desensitization of ZnR/GPR39, TAMR cells 
were incubated with Zn2+ for a prolonged period, using a lower concentration to avoid toxicity (100 μM for 
25 min). Cells that were pre-incubated with Zn2+ exhibited lower response to Zn2+ compared to the response in 
control cells that were maintained in Ringer’s solution for the same time (Fig. 2C,D). To assess the recovery of the 
receptor, cells were returned to growth medium and imaged 24 hours later. A slightly increased Ca2+ response 
was triggered by Zn2+ (200 μM) in the cells that underwent desensitization (Fig. 2C,D). This suggests that the 
prolonged exposure to Zn2+ induces profound ZnR/GPR39 activation, likely depleting the intracellular Ca2+ 
stores in addition to the desensitization.
Transfection of MCF-7 cells with mCherry-tagged ZnR/GPR39 was followed by cell surface expression of 
the tagged receptor, but the mCherry-tagged vector (control) was accumulated within the cytoplasm of MCF-7 
cells (Fig. 2E). The ZnR/GPR39 expressing MCF-7 cells exhibited Zn2+-dependent Ca2+ responses, monitored 
with Fura-2 (Fig. 2F,G). Finally, ZnR/GPR39 desensitization of the response was also monitored in MCF-7 
mCherry-tagged ZnR/GPR39 cells that were pre-incubated with Zn2+ (Fig. 2G). Altogether, overexpression of 
ZnR/GPR39 in MCF-7 cells or induction of its expression in TAMR cells induces Zn2+-dependent Ca2+ signaling.
To determine if Zn2+-dependent signaling is generally mediated in breast cancer cells, we studied ZnR/
GPR39 activity in BT20, MDA-MB-453 cell lines, which are ERα and PR negative, but overexpress some level 
of HER2 (CCLE microarray data; https://portals.broadinstitute.org/ccle)45. In both BT20 and MDA-MB-453 
cell lines, GPR39 mRNA levels were significantly higher than in MCF-7 cells, and its levels were reduced by 
siGPR39 (Fig. 3A). The siGPR39 construct also reduced expression of the mCherry-tagged GPR39 (inset). To 
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Figure 1. Extracellular Zn2+ triggers Ca2+ responses in TAMR but not in MCF-7 cells. (A) TAMR or MCF-7 
cells, loaded with Fura-2, were imaged, and Zn2+ (200 μM) was applied at the indicated time. Representative 
Ca2+ response averaged over 10–15 cells is shown (left panel). The average rate of signal rise is shown in the bar 
graph (right panel, n = 5 slides for each condition in 4 independent experiments, p < 0.05 t-test). Inset shows 
a representative Ca2+ response triggered by the purinergic metabotropic receptor agonist, ATP (25 μM). (B) 
Quantitative PCR analysis of GPR39 mRNA levels in the MCF-7 versus TAMR cells (n = 3, p < 0.05 t-test). (C) 
Dose response analysis of the Zn2+-dependent Ca2+ response in Fura-2 loaded cells was performed, using the 
paradigm described in A, for TAMR and MCF-7 cells (n = 4, p < 0.05 t-test). (D) Using thapsigargin (200 nM) 
and ATP (25 µM), as indicated, the intracellular Ca2+ stores were depleted, and subsequent baseline fluorescent 
signal indicated removal of cytoplasmic Ca2+. Then, Zn2+ was applied as in A; representative traces from TAMR 
and MCF-7 cells are shown. (E) Ca2+ stores were depleted as in D., and Zn2+ (200 μM) was applied in the presence 
(black) or absence (orange) of the ionophore pyrithione (5 μM). The cell permeable chelator TPEN (10 μM) was 
finally added. Representative response of Fura-2 signal is shown. (F) Cells loaded with the Zn2+-sensitive dye, 
FluoZin3, were pre-treated with Zn2+ alone or in the presence of pyrithione (5 μM, 2 min). Cells were then imaged 
and TPEN (10 μM) was applied, representative traces are shown. Averaged rates of fluorescence decrease are shown 
in the insert (n = 5 coverslips in 4 independent experiments, p < 0.05 t-test). Bottom panel shows representative 
images of FluoZin-3 fluorescence in cells pre-treated with Zn2+ alone or in the presence of pyrithione (5 μM, 2 min).
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Figure 2. ZnR/GPR39 mediates Zn2+-dependent intracellular Ca2+ signaling in TAMR cells. (A) Representative 
Fura-2 fluorescent signal of TAMR cells pre-treated with the Gαq inhibitor, YM-254890 (1 μM, 5 min) or 
without it (control). At the indicated time, Zn2+ (200 μM) was applied. Inset shows the Ca2+ response of YM-
254890 treated cells to the purinergic agonist ATP (25 μM). (B) Representative Ca2+ response of TAMR cells 
transfected with siGPR39 or a scrambled control (siControl) to Zn2+ (200 μM, as indicated, left panel). Right 
panel (top) shows the response of siGPR39 cells to the purinergic agonist ATP (25 µM). Right panel (bottom) 
depicts mRNA level of ZnR/GPR39 in siGPR39 and siControl cells (n = 4 coverslips for each condition, in 6 
independent experiments, p < 0.05 t-test). (C) TAMR cells were pre-treated with lower concentration of Zn2+ for 
a prolonged time (100 μM for 25 min, 37 °C). Cells were then maintained in Zn2+-free Ringer’s solution for 30 min 
(desensitized) or returned to the incubator for 24 h (recovery, n = 4 coverslips), and subsequently ZnR/GPR39 
activation was monitored using the paradigm described in Fig. 1. Representative Ca2+ signals in control cells, 
desensitized cells and cells following recovery are shown. (D) Average rates of initial Ca2+ response as determined 
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verify that Zn2+ permeation is not induced in these cells, intracellular Ca2+ stores were depleted, using thapsi-
gargin and ATP, and subsequent addition of Zn2+ did not trigger a fluorescent signal rise (Fig. 3B). We then asked 
if ZnR/GPR39 is active in these cells by monitoring the Zn2+-dependent Ca2+ release in Fura-2 loaded cells. 
Extracellular Zn2+ triggered Ca2+ responses in MDA-MB-453 (Fig. 3C) and BT20 (Fig. 3D), ER negative cells, 
and this Zn2+-dependent Ca2+ signaling was abolished in cells transfected with siGPR39 constructs (Fig. 3C,D). 
Furthermore, the ERα negative JIMT-1 cells also exhibited Zn2+-dependent Ca2+ responses (Fig. 3E), but the ERα 
positive T47D cells did not show Zn2+-dependent signaling (Fig. 3F), although both cell lines show high levels 
of GPR39 mRNA (CCLE microarry data; https://portals.broadinstitute.org/ccle). Importantly, non-transformed 
MCF-10A cells did not exhibit Zn2+-dependent Ca2+ responses (Fig. 3G). As a control, ATP induced robust Ca2+ 
responses in T47D and MCF-10A cells, indicating that the purinergic pathway activated by ATP is intact. Our 
results suggest a role for ZnR/GPR39 in mediating Ca2+ signaling in ER negative breast cancer cells, but not in 
cells that are ER positive.
We then asked whether ZnR/GPR39 expression is associated with human breast cancer malignancy. We ini-
tially monitored the expression level of ZnR/GPR39 by immunostaining of breast cancer biopsies (http://www.
biomax.us/tissue-arrays/Breast/BR1504a). Higher ZnR/GPR39 expression is seen in grade 3 biopsies compared to 
grade 2 (Fig. 4A, p = 0.04 by Fisher’s exact test) only in the ER-negative tissues, but not in the ER-positive tissues. 
Due to the small number of samples available in the tissue slide, we performed analysis for GPR39 expression using 
two independent gene expression datasets. In the HER2-normal breast cancer patients cohort, GDS405746, gene 
profiling analysis was determined on pre-treatment biopsies, thus representing the initial expression level of the 
proteins. The dataset includes 103 ER-positive and ER-negative subtypes of breast cancer tissue mostly of grade 2 
or grade 3. Analysis of all grade 3 versus grade 2 tissues indicated that there is a tendency towards increased 
GPR39 expression that did not reach statistical significance (p = 0.062). Interestingly, ER-positive tissues showed 
similar GPR39 expression in both grades, but the expression level of GPR39 in grade 3 ER negative tissues was 
significantly higher than in grade 2 ER-negative tissues (left panel Fig. 4B, p = 0.04). Importantly, expression of 
another Gq coupled receptor, the purinergic P2XR1, did not show a grade-dependent change (p = 0.3 for ER 
negative samples between grade 2 and grade 3, right panel Fig. 4B). To extend this mRNA expression analysis, 
we also explored an independent cohort of cancer patients, and compared the levels of GRP39 mRNA (RNA 
seq V2 RSEM) in breast cancer patients with stage 2 and stage 3 from the TCGA (www.cbioportal.org)47–49. 
Specifically, analysis of 197 ER-negative breast cancer patients showed that GPR39 was significantly higher in 
stage 3 compared to stage 2 (p = 0.022 Welch’s t-test, Fig. 4C). Levels of GPR39 mRNA expression were not sig-
nificantly different in ER-positive biopsies from this cohort. These results suggest that increased expression of 
GPR39 is linked to breast cancer aggressiveness, particularly in ER-negative tumors.
ZnR/GPR39 activates kinase signaling in breast cancer cells. We then asked if the enhanced activity 
of PI3K/AKT and MAPK/ERK1/2 pathways in breast cancer cells can be mediated via ZnR/GPR39. To specifi-
cally assess the role of ZnR/GPR39, we silenced ZnR/GPR39 expression in TAMR cells and monitored AKT and 
ERK1/2 phosphorylation, following a brief application of Zn2+ (200 μM, 30 s). An increase in phosphorylated 
AKT (pAKT) was observed in siControl cells, but not in siGPR39 transfected cells, that were treated with Zn2+ 
(Fig. 5A). To determine if a synergistic crosstalk between ZnR/GPR39 and IGF-1R can enhance PI3K/AKT acti-
vation, we also applied recombinant IGF-1 with or without Zn2+. While pAKT levels were higher when IGF-1 was 
applied, compared to Zn2+, co-application of both ligands did not further increase pAKT expression. Importantly, 
silencing of ZnR/GPR39 did not inhibit pAKT upregulation by IGF-1, although it abolished the Zn2+-dependent 
activation. Thus, Zn2+ via ZnR/GPR39 activated the PI3K/AKT independent of the IGF-1R pathway. When Zn2+ 
was applied in the presence of the Gαq inhibitor, YM-25489038, the Zn2+-dependent increase in pAKT was abol-
ished (Fig. 5B), suggesting that ZnR/GPR39 signaling induces the phosphorylation. Increased phosphorylation of 
mTOR, which is downstream to the PI3K, was also monitored following treatment with Zn2+ (200 μM) in control 
TAMR cells, but not in cells treated with Gαq inhibitor (Fig. 5C). Similarly, Zn2+-induced increase in phospho-
rylated ERK1/2 (pERK1/2) that was reversed by the Gαq inhibitor (Fig. 5D) and by transfection with the siGPR39 
construct (Fig. 5E). Finally, pERK1/2 was also increased in BT20 cells transfected with siControl but not in cells 
transfected with siGPR39 constructs (Fig. 5F), which attenuated the Zn2+-dependent Ca2+ response (Fig. 3F). 
Thus, Zn2+ and ZnR/GPR39, via a Gαq-dependent pathway, upregulate the PI3K/AKT and MAPK pathways in 
TAMR and BT20 breast cancer cells.
ZnR/GPR39 enhances proliferation and invasiveness of breast cancer cells. To determine if 
activation of ZnR/GPR39 signaling controls breast cancer cell growth and invasion, we initially compared the 
Zn2+-dependent cell growth rates in ZnR/GPR39-expressing TAMR cells, and MCF-7 cells deficient in this 
receptor. Cells were treated daily, for 7 consecutive days, with Zn2+ (200 μM, 2 min) or EDTA (100 μM, 2 min) a 
from A-C. (n = 4 coverslips for each condition, in 6 independent experiments, p < 0.05 t-test). (E) Fluorescent 
imaging of MCF-7 cells transfected with an mCherry- vector or mCherry-ZnR/GPR39. (F) Representative 
Fura-2 signals, indicating Ca2+ responses, of MCF-7 cells transfected with the mCherry-vector or mCherry-ZnR/
GPR39, following application of Zn2+ (200 μM, at the indicated time). Inset shows the purinergic response of 
the mCherry-vector cells, indicating that the metabotropic pathway is intact in these cells. (G) Cells expressing 
mCherry-vector or mCherry-ZnR/GPR39 were desensitized using the paradigm described in C. After 30 min in 
Zn2+-free Ringer’s solution, Fura-2 loaded cells were imaged and the initial rate of the response to Zn2+ (200 μM) 
was determined. The average of the initial rate of the Zn2+-dependent Ca2+ response in desensitized cells or 
controls is shown. (n = 5 coverslips for each condition, in 4 independent experiments, p < 0.05 ANOVA).
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paradigm that does not induce desensitization of ZnR/GPR39 or Zn2+ permeation into the cells. To chelate extra-
cellular Zn2+, which is a contaminant in many solutions or may be released endogenously from cells, we applied 
the cell impermeable chelator EDTA that is a high affinity Zn2+ chelator (Kd 10−13 M50), at a concentration that 
does not affect extracellular Ca2+, as previously done37,39,40. Application of extracellular Zn2+ did not significantly 
enhance proliferation of MCF-7 cells (Fig. 6A), but did enhance proliferation of TAMR cells by more than 3-fold 
already on the 3rd day of treatment (Fig. 6B). Importantly, the short Zn2+ transients applied daily did not desen-
sitize or attenuate ZnR/GPR39 Ca2+ responses (top right panel, 6B). In the TAMR cells that express ZnR/GPR39, 
Figure 3. ZnR/GPR39 signaling is found in estrogen independent cell lines. (A) The mRNA level of GPR39 
was determined using q-PCR in MCF-7, BT20 and MDA-MB-453 breast cancer cells, following transfection 
with siGPR39 constructs or scrambled (siControl) constructs (n = 3 for each cell line, p < 0.05 t-test). Right 
panel shows HEK293 cells transfected with mCherry-tagged GPR39 with siSCR or siGPR39 co-transfection, 
indicating that the siGPR39 efficiently attenuates ZnR/GPR39 expression. Representative confocal images 
showing Dapi (blue) nuclear staining and mCherry (red) indicating ZnR/GPR39 expression, which was 
abolished by siGPR39. (B) Fura-2 fluorescence was monitored in BT20 and MDA-MB-453 cells following Ca2+ 
store depletion (using 200 nM thapsigargin and 25 µM ATP, as in Fig. 1C), and application of Zn2+ (200 µM). 
(C) Representative Ca2+ response from siGPR39 or siControl MDA-MB-453 cells loaded with Fura-2 following 
application of Zn2+ (200 μM, at the indicated time). Average initial rates of the Ca2+ responses are shown in 
the right panel (n = 4 coverslips for each condition, in 3 independent experiments, p < 0.05 ANOVA). (D) 
Representative Ca2+ response to application of Zn2+ (200 μM, at the indicated time) in BT20 cells, loaded with 
Fura-2, transfected with several siGPR39 or siControl constructs. Average initial rates of the Ca2+ responses are 
shown in the right panel (n = 4 coverslips for each condition, in 3 independent experiments for WT, siGPR39 
and siControl and 2 independent experiments for siGPR39_1 and siGPR39_2, p < 0.05 ANOVA). (E–G). 
Representative Ca2+ responses obtained as in C. using JIMT-1 (E); T47D (F); or MCF-10A (G) cells loaded with 
Fura-2 and treated with Zn2+ (200 μM) and ATP (25 µM), as indicated. (n = 3 coverslips for each condition, in 2 
independent experiments).
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cell growth was not enhanced by Zn2+ when applied in the presence of the Gαq inhibitor (YM-254890, 10 μM, 
30 min, middle panel). To determine the effect of Zn2+ compared to EDTA, we analyzed the ratio between the 
numbers of cells treated with Zn2+ or EDTA on each day. We found that Zn2+-dependent cell growth in the 
TAMR, ZnR/GPR39-expressing, breast cancer cells was much faster compared to MCF-7 cells (Fig. 6C). We then 
determined the specific role of ZnR/GPR39 using shGPR39 silencing with lentiviral constructs, more efficient 
than the siGPR39 transfection. Infection of the cells with the lentiviral constructs abolished the Zn2+-dependent 
Ca2+ responses in shGPR39 TAMR cells, but not in the shSCR cells infected with a scrambled construct, sug-
gesting that ZnR/GPR39 signaling is absent in the shGPR39 cells (Fig. 6D, right panel). Growth rates of TAMR 
cells infected with shSCR showed Zn2+-dependent enhancement of cell numbers compared to EDTA treated 
cells; but the effect of Zn2+ was significantly attenuated in the ZnR/GPR39 silenced (shGPR39) cells (Fig. 6D). 
We also compared proliferation rates of ZnR/GPR39 expressing MDA-MB-453 and BT20 breast cancer cells 
following daily treatment with Zn2+ (200 μM, 2 min) or EDTA (100 μM, 2 min). In both ZnR/GPR39-expressing 
cell lines, Zn2+ treatment significantly increased the number of cells compared to EDTA (Fig. 6E,F). While the 
Zn2+ increased cell growth was clearly seen in the MDA-MB-453 cells already following one daily treatment 
(Fig. 6G), the BT20 cells presented very slow growth rates and Zn2+ slightly, albeit significantly, enhanced BT20 
cell growth only the 5th day of treatment (Fig. 6F). These results suggest that Zn2+ enhances cell growth in ZnR/
GPR39-expressing breast cancer cells.
We next examined if Zn2+ controls the invasiveness of TAMR or MCF-7 cells by monitoring their growth into 
a matrigel matrix following daily Zn2+ or EDTA treatments (same paradigm described above). To specifically 
determine the role of ZnR/GPR39, Zn2+ was applied in the presence or absence of the Gαq inhibitor. TAMR cells 
that were treated with Zn2+ showed about two-fold higher invading cell numbers, and this effect was reversed 
by application of the Gαq inhibitor (Fig. 6G). In contrast, Zn2+ did not enhance MCF-7 invasiveness compared 
to control cells, nor was this affected by the Gαq inhibitor (Fig. 6H). Therefore, we suggest that Zn2+ enhances 
invasiveness of TAMR cells, but not of MCF-7 cells, via the Gαq signaling triggered by ZnR/GPR39.
Figure 4. ZnR/GPR39 expression is increased in higher grade breast cancer tissue. (A) An array of breast 
cancer biopsies (http://www.biomax.us/tissue-arrays/Breast/BR1504a) was stained for ZnR/GPR39. Average 
staining level, above a threshold, in ER negative samples of grade 2 and grade 3 tissues is shown (scale bar 
shown on image). Representative images of ZnR/GPR39 staining and hematoxylin eosin stain (from the 
company site) are shown (bottom panel). (B) Analysis of ZnR/GPR39 mRNA level in ER-positive or negative, 
HER2-normal, breast cancer grade 2 (white) or 3 (grey) tumors (GDS4057 cohort, left panel). Note that a 
significant increase is seen in ZnR/GPR39 expression in ER-negative grade 3 tumors (p < 0.05 t-test). Right 
panel shows the analysis of mRNA level of P2XR1 purinergic receptor on the same cohort. (C) Analysis of ZnR/
GPR39 mRNA level in ER-positive or negative, breast cancer stage 2 (white) or 3 (grey) tumors (TCGA cohort, 
p < 0.05, Welch’s t-test).
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Figure 5. Activation of PI3K and MAPK pathways by ZnR/GPR39 in estrogen independent breast cancer cells.  
(A) Immuno-blots of phospho and total AKT in TAMR cells transfected with siGPR39 or siControl and treated with 
Zn2+ (200 μM) or IGF-1 (100 nM) or a combination of Zn2+ and IGF-1 or EDTA (100 μM) as control (top panel). 
Bottom panel shows densitometry analysis. (B) Immunoblot and denistometry analysis of pAKT and tAKT, as in A, 
of TAMR cells treated with or without the Gαq inhibitor, YM-254890 (1 μM, 30 min) and following Zn2+ (200 μM) 
application. (C) Immunoblot and denistometry analysis of phospho-mTOR levels in TAMR cells treated with or 
without the Gαq inhibitor, YM-254890 (1 μM, 30 min) and following Zn2+ (200 μM) application. (D) Immunoblot 
and densitometry analysis of pERK1/2, relative to total ERK1/2 in TAMR cells treated with or without the Gαq 
inhibitor, YM-254890 (1 μM, 30 min) and following Zn2+ (200 μM) application. (E) Immunoblot and denistometry 
analysis of pERK1/2, relative to total ERK1/2 in TAMR cells transfected with siGPR39 or siControl and treated with 
or without Zn2+ (200 μM). (F) Immunoblot and denistometry analysis of pERK1/2, relative to total ERK1/2 in BT20 
cells transfected with several siGPR39 constructs or siControl and treated with or without Zn2+ (200 μM) (n = 2 
independent experiments). Densitometry quantification in the bar graphs are averages of at least n = 3 independent 
experiments performed in triplicates for each condition (p < 0.05 ANOVA). Each blot presented was cropped from 
one original blot at one exposure. Original, full blots are presented in supplementary material.
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Figure 6. Cell growth and invasion are increased by ZnR/GPR39. Cell growth, as measured using SRB levels, 
in cells treated daily with Zn2+ (200 μM, 2 min) to activate ZnR/GPR39 versus EDTA (100 μM, 2 min) used 
to chelate residual or released Zn2+. (A) Averaged count of numbers of MCF-7 cells following Zn2+ or EDTA 
daily treatment (p < 0.05 t-test, between treatments for each day). (B) Left panel shows averaged TAMR cell 
numbers, as in A. (p < 0.05 t-test, between treatments for each day). Middle panel shows the cell numbers in 
cells pre-treated with the Gαq inhibitor (YM-254890, 10 μM, 30 min) prior to the daily treatment with Zn2+ 
(200 μM, 2 min. n = 5). Bottom right panel shows representative images of the plate following SRB staining 
on day 0 (no Zn2+ treatment) versus day 7 of treatment. Top right panel shows representative Ca2+ responses 
monitored using Fura-2 fluorescence as in Fig. 1, in TAMR cells that were pre-treated with Zn2+ (200 μM, 
2 min) 24 hrs. prior the imaging (n = 4 coverslips). (C) Analysis of A-B showing the daily fold increase in cell 
number, as monitored with SRB, following Zn2+ treatment compared to EDTA treatment (p < 0.05 t-test, 
between daily treatment of MCF-7 and TAMR cells). (D) TAMR cells were infected with shGPR39 lentiviral 
constructs or shSCR (scambled control), as described. Cell growth analysis using SRB was done as in A, and 
number of cells treated with Zn2+ were normalized compared to cells treated with EDTA (as in C; p < 0.05 
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Discussion
The tamoxifen-resistant TAMR cells exhibited cellular Zn2+ dyshomeostasis and increased CK2 phosphoryl-
ation22,23 that was linked to a more aggressive phenotype of these cells25. A role for ZnR/GPR39 in enhancing 
signaling and cell growth was not addressed. We show that ZnR/GPR39 expression and function are increased 
in TAMR cells, compared to the original MCF-7 cells. Importantly, changes in intracellular Zn2+ do not induce 
direct ZnR/GPR39 signaling33,35, but the higher levels of accumulated Zn2+20,51 may suggest that transient extra-
cellular changes by release of Zn2+39 can trigger ZnR/GPR39 activation and enhanced cell growth. Importantly, 
ZnR/GPR39 is essential for Zn2+-dependent signaling leading to enhanced cell growth in the TAMR cells as well 
as in MDA-MB-453 cells and BT20 cells. Cell signaling and subsequent increases in proliferation rate were trig-
gered by transient extracellular Zn2+ treatment in ERα-negative breast cancer cells expressing a functional ZnR/
GPR39. Thus, we suggest that changes in Zn2+ homeostasis in breast cancer tissue, together with increased ZnR/
GPR39 expression yield an alternative pathway leading to cell growth.
The affinity of ZnR/GPR39 is modified in various tissues, such that in colonocytes the apparent Km was 
80 ± 15 µM, but in keratinocytes Km was two orders of magnitude higher, 450 ± 50pM. Both concentrations are 
physiologically relevant in the relative tissue34,36,52. The different affinities of ZnR/GPR39 may be regulated by 
its interaction with other GPCRs as is common in this family of receptors53. Alternatively, the presence of other 
ions may modulate ZnR/GPR39 affinity to Zn2+38,52. Interestingly, the Ca2+ sensing receptor, which interacts 
with ZnR/GPR3938, has been shown to promote breast cancer54. The differences in the apparent affinity and 
maximal activity of ZnR/GPR39 in TAMR versus MCF-7 cells may also result from differences in mRNA levels. 
Importantly, the concentration of “elemental zinc” in breast cancer tissue is estimated to be of about 100 µM55, 
as measured by X-ray fluorescence. This measurement does not distinguish between the localization (extra or 
intracellular or organellar) or the binding of ionic Zn2+ to proteins. Nevertheless, and in agreement with reports 
describing changes in vesicular Zn2+ as well as “elemental zinc” in breast cancer cells, potential Zn2+ release from 
protein or vesicles may be sufficient for triggering ZnR/GPR39 activation. The release of Zn2+ induces transient 
changes in extracellular Zn2+ because this ion undergoes re-uptake into the cells via ZIP transporters or is che-
lated by binding to proteins15,56. The increase in ZnR/GPR39 level in more aggresive cancer cells taken together 
with such transient Zn2+ changes may therefore play a role in enhanced growth and invasiveness.
Analysis of human breast cancer tissues, using the GDS4057 cohort46 or the TCGA49 available data, indi-
cated that in ERα-negative tissues increased ZnR/GPR39 expression is linked to more aggressive phenotypes. 
Importantly, in ERα-positive biopsies from both cohorts the levels of ZnR/GPR39 expression was not signifi-
cantly different between phenotypes. In addition, using human breast cancer tissue staining, we also show an 
increase in ZnR/GPR39 expression in grade 3 tissues compared to grade 2. Changes in the expression of ZnR/
GPR39 were previously associated with more aggresive cancers. For example, GPR39 was suggested as a bio-
marker for ovarian cancer since mRNA level is 6-fold higher in ovarian cancer tissue samples compared with 
normal tissue57. Similar increase in GPR39 expression was found in human esophageal squamous cell carci-
noma and was linked to enhanced cell growth in the KYSE30 esophageal carcinoma cell line58. While a direct 
role for Zn2+ was not determined, upregulation of GPR39 was also demonstrated in aggressive cancer cell lines 
of breast, ovarian and prostate, and melanoma59 and was linked to EGFR transactivation60. Moreover, GPR39 
overexpression in porcine intramuscular preadipocytes enhanced their differentiation and proliferation via the 
PI3K pathway. Finally, GPR30 is an estrogen-specific orphan GPCR61 that triggers cAMP release in SKBR3 breast 
cancer cell line62. GPR30 also mediates proliferative effects, induced by 17β-estradiol and hydroxytamoxifen, 
in endometrial cancer cells63. Our results indicate that ZnR/GPR39 signaling, triggered by extracellular Zn2+, 
leads to activation of the MAPK and PI3K/AKT pathways, both closely associated with cell growth and survival 
in cancer. We further show that ERα-negative TAMR, BT20 and MDA-MB-453 cells, exhibit increased prolifer-
ation rates following ZnR/GPR39 activation, compared to the ERα-positive MCF-7 cells that do not have ZnR/
GPR39 signaling. Moreover, invasion of TAMR cells following ZnR/GPR39 activation was increased, and this 
was abolished by the Gq inhibitor or in the MCF-7 cells, suggesting that ZnR/GPR39 signaling is essential for 
Zn2+-dependent increased migration. The data presented here support our hypothesis that ZnR/GPR39 mediates 
signaling pathways leading to aggressive growth in breast cancer cells, particularly in the absence of the estrogen 
receptor pathway. Thus, ZnR/GPR39 may provide an alternative pathway that contributes to increased malig-
nancy in breast cancer.
Activation of the PI3K/AKT pathway in breast cancer cells is not only enhancing cell survival but was also 
associated with endocrine resistance8. Activation of an upstream receptor such as the IGF-1 receptor is associated 
t-test, between daily treatment of shSCR and shGPR39 cells). Right panel shows representative Ca2+ responses 
monitored using Fura-2 fluorescence in the shGPR39 and shSCR cells, indicating silencing abolished the Zn2+-
dependent Ca2+ signaling. (n = 2 independent experiments (p < 0.05 t-test, between shSCR and shGPR39 each 
day). (E) Averaged MDA-MB-453 cell numbers for Zn2+ or EDTA treatment on each day, the right panel shows 
representative images of the plate following SRB staining. (p < 0.05 t-test, between treatments) (F) Averaged 
BT20 cell numbers for Zn2+ or EDTA treatment on each day; the right panel shows representative images 
of the plate following SRB staining. (p < 0.05 t-test, between treatments) (G) Migration of cells via matrigel 
was determined, for TAMR cells treated with or without the Gαq inhibitor, YM-254890 (1 μM, 30 min). Cells 
were treated with Zn2+ (200 μM, 2 min) or EDTA (100 μM, 2 min) as control, and cells that migrated through 
Matrigel were counted (20×, DAPI staining, inversed greyscale image). The average numbers of cells are shown 
in the bar graph (left panel). Right panel shows a representative image of the cells that invaded through Matrigel 
at 72 h following treatment (Zn2+ or EDTA). (n = 3 independent experiments, p < 0.05 ANOVA). (H) Migration 
of MCF-7 cells using the paradigm described in F.
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with the initial upregulation of this pathway64. Our results show that Zn2+ can similarly activate the PI3K pathway 
via ZnR/GPR39 and, that this is independent of the IGF-1 pathway. Activation of both AKT and mTOR, as well as 
the MAPK pathway, by Zn2+, were mediated by ZnR/GPR39-dependent activation of a Gαq pathway. This path-
way may also lead to phosphorylation of ZIP7 that induces subsequent Zn2+ release and prolonged activation of 
PI3K and MAPK22. Both, the MAPK and PI3K pathways, play a prominent role in breast cancer tumorigenesis8,65 
and inhibitors of these pathways have been suggested for use in addition to the antihormone therapy. However, 
direct inhibition of molecules in the PI3K or MAPK pathways leads to activation of negative feedback loops 
which further enhance cell growth66–69. Our study suggests that in breast cancer tissue, elevated Zn2+ levels and 
increased ZnR/GPR39 expression may provide an alternative pathway to PI3K and MAPK activation. Activation 
of ZnR/GPR39 by endogenous Zn2+ in breast cancer tissue may occur following specific release of Zn2+ from 
vesicles16,31,51 or cell injury and death39.
Altogether the results presented support an important role for ZnR/GPR39 in mediating Zn2+-signaling that 
is leading to enhanced growth and invasiveness of breast cancer cells. Changes in the expression of ZnR/GPR39 
in breast cancer cells following loss of the ER signaling may provide a circumventing pathway for metabotropic 
signaling activation and enhanced cell growth in breast cancer. As such, ZnR/GPR39 may provide an upstream 
target for novel therapeutic approaches for hormone resistant breast cancer.
Methods
Cell culture. MCF-7 cells were grown in standard RPMI medium (Gibco, Scotland) supplemented with 5% 
(v/v) fetal calf serum (Biological Industries, Israel) and 1% pen-strep solution (10000 U/ml penicillin, 10000 µg/
ml streptomycin, Sigma-Aldrich, Israel) and 1% L-Glutamine. TAMR cells (a gift from JMW Gee, Cardiff 
University) derived from MCF-7 cells that were grown for 6 months in tamoxifen antihormone treatment70, were 
grown in RPMI medium without phenol red (Gibco, Scotland), supplemented with 5% (v/v) charcoal stripped, 
steroid-free, fetal calf serum (Biological Industries, Israel), 1% pen-strep solution, 2% L-Glutamine (200 mM) 
and 4-hydroxytamoxifen (4-OHTAM, 0.1 µM in ethanol, Sigma-Aldrich, Israel). For comparison between the 
cell types, MCF-7 cells were grown in the same medium as TAMR cells, but without tamoxifen. MDA-MB-453 
and T47D cells were grown in standard RPMI medium (Gibco, Scotland), supplemented with 10% (v/v) fetal 
calf serum (Biological Industries, Israel) and 1% pen-strep solution. BT20 cells were grown in Eagle’s Minimum 
Essential Medium (EMEM, Biological Industries, Israel) supplemented with 10% (v/v) fetal calf serum (Biological 
Industries, Israel) and 1% pen-strep solution. All cells were grown in a 5% CO2 humidified atmosphere at 37 °C. 
JIMT-1 cells were grown in Dulbecco modified Eagle medium (DMEM, Biological Industries, Israel) supple-
mented with 10% (v/v) fetal calf serum (Biological Industries, Israel), 1% pen-strep solution (10000 U/ml pen-
icillin, 10000 µg/ml streptomycin, Sigma-Aldrich, Israel) and 1% L-Glutamine. MCF-10A cells were grown in 
DMEM/F12 (Gibco, Scotland) supplemented with 10% (v/v) fetal calf serum (Biological Industries, Israel), 1% 
pen-strep solution (10000 U/ml penicillin, 10000 µg/ml streptomycin, Sigma-Aldrich, Israel) 1% L-Glutamine, 
EGF (20 ng/ml), Hydrocortisone (0.5 mg/ml) and human Insulin (10 µg/ml).
Cell transfection and infection. For GPR39 silencing, TAMR, MCF-7, MDA-MB-453 and BT20, cells 
were seeded in 60 mm plates, 24 h prior to transfection in media containing serum but without antibiotics. Cells 
were transfected with siRNA using Lipofectamine 2000 (Thermo-Fisher Scientific, MA, USA) according to the 
manufacturer’s protocol. The siRNA constructs used for GPR39 silencing: 5′-CCAUGGAGUUCUACAG CAU-
3′ (siGPR39, Sigma-Aldrich, Israel), 5′-CUCCCAAAUCAUUGAUCACAGUCAT-3′ (siGPR39_1, Integrated 
Data Technologies, Belgium), 5′-GCAUCAUCUGGAAUCCCCUGACCAC-3′ (siGPR39_3, Integrated 
Data Technologies, Belgium), and siRNA control (scrambled) was 5′- GCCCAGAUCCCUGUACGU-3′. 
Cells were used for experiments 48 h after transfection. For GPR39 overexpression, MCF-7 cells were seeded 
in 60 mm plates, 24 h prior to transfection, in RPMI phenol-free media containing serum but without anti-
biotics. Cells were transfected with a plasmid carrying GPR39 with m-Cherry sequence or m-Cherry vector 
alone, as control. Transfections were done with TransIT-BrCa (Mirus Bio, WI, USA), according to the man-
ufacturer’s protocol. Experiments were performed 48 h following transfection. TAMR cells were infected 
using MISSION Lentiviral Transduction Particles (Sigma-Aldrich) according to manufacturer protocol. 
Briefly, 50,000 cells were seeded a day before infection on 24-well plates. Infection was carried out using five 
lentivirus clones carrying DNA sequences coding for shRNA compatible with hGPR39 (shGPR39_1:C-
CGGCCTCCAATATGTCCATCTGTACTCGAGTA CAGATGGACATATTGGAGGTTTTT; shG-
PR39_2:CCGGGAACATGATGCAGGTGCTC ATCTCGAGATGAGCACCTGCATCATGTTCTTTTT; 
shGPR39_3:CCGGGCTGCAGAAGA AAGGATACTTCTCGAGAAGTATCCTTTCTTCTGCAGCTTTTT; 
shGPR39_4:CCGGG TACCTGATCATCTTCGTGATCTCGAGATCACGAAGATGATCAGGTACTTTTT; 
shGPR39_5:CCGGGAACATGATGCAGGTGCTCATCTCGAGATGAGCACCTGCATCATGTTCTTTTT, or 
scrambled sequences. Twelve hours post infection the medium was replaced with growth medium.
Fluorescent Imaging. The imaging system consisted of an Axiovert 100 inverted microscope using a 
20× objective (Zeiss, Germany), Polychrome V monochromator (TILL Photonics, Germany) and a SensiCam 
cooled charge-coupled device (PCO, Germany). Fluorescent imaging measurements were acquired with Imaging 
Workbench 5 (Indec, USA). All results shown are the means of at least three independent experiments, with aver-
aged responses of 20 cells in each experiment. Bar graphs show the initial rates of fluorescence change averaged 
over at least n slides from 3 independent experiments, as mentioned in figure legends.
For Ca2+ imaging. cells were seeded on coverslips at least 24 h prior to the experiment, and loaded with 
Fura-2 acetoxymethyl ester (AM; 25 min 2 μM; TEFLabs Inc., TX, USA) in Ringer’s solution with 0.1% BSA 
(Bovine Serum Albumin, Sigma-Aldrich, Israel), and subsequently washed for at least 15 min. Coverslips were 
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then mounted in a microscope chamber that allowed rapid solution exchange. Fura-2 was excited at 340 nm and 
380 nm and imaged with a 510 nm long-pass filter. Activation of ZnR/GPR39 was triggered by application of 
200 µM Zn2+ in Ca2+ free Ringer’s solution71,72 for 30 s up to 2 min, as indicated in figures, a paradigm that did not 
induce cytoplasmic Zn2+ rise (see Fig. 1C,D). The initial rate of the fluorescent signal rise, calculated over 20 s, 
was used to determine the response.
For Zn2+ imaging. cells were seeded as described and loaded with Fluozin-3 (AM; 30 min 25 μM; Invitrogen, 
CA, USA) in Ringer’s solution with 0.1% BSA and subsequently washed for at least 25 min. The excitation was 
at 480 nm, and emission was monitored through a 510 nm long- pass filter. The cells were incubated for 2 or 
20 minutes with 100 µM Zn2+ and the cell permeable Zn2+ chelator TPEN (N,N,N′,N′-tetrakis (2-pyridylmethyl) 
ethylenediamine, 10 μM, Sigma-Aldrich, Israel) was added while monitoring cellular fluorescence. Image acqui-
sition was done at 20× using an Olympus BX51 fluorescent microscope with a CCD. Quantitative analysis was 
performed by counting pixels that were stained above a predetermined threshold, normalized to the number of 
cells in the slide and compared to control values.
Western blots. Protein expression was monitored using western blot analysis. Cells were treated with Zn2+ 
or control (as described) and harvested into lysis buffer (0.5% Deoxycholic acid, 25 mM NaF, 10 mM Na3PO4, 
1 mM sodium-orthovanadate, 100 mM NaCl, 5 mM EDTA, 5 mM EGTA, 2% (v/v) Triton X-100) in the presence 
of Protease Inhibitor Cocktail (1:50 Complete, Sigma-Aldrich, Israel). For testing phosphorylation of ERK1/2 or 
AKT the buffer also included PNPP (20 mM, Sigma-Aldrich, Israel), sodium vanadate (1 mM) and NaF (25 mM). 
Lysates were placed on ice for 10 min and then centrifuged for 30 min (12,000 rpm) at 4 °C. Supernatants (cyto-
solic fraction) were collected, protein concentrations were determined using Bio-Rad protein assay (Bio-rad, 
CA, USA), SDS sample buffer was added, and samples were boiled for 5 min and then frozen at −80 °C until 
used. Kinase phosphorylation was assayed using cell lysates (25 μg), separated on a SDS-PAGE (10% for ERK1/2, 
AKT and occludin or 7.5% for mTOR) and analyzed using antibodies raised against the doubly phosphorylated 
ERK1/2, total ERK1/2 and total AKT (Sigma-Aldrich, Israel) or phosphorylated AKT (Santa-Cruz Biotechnology, 
TX, USA) phosphorylated mTOR (1:500, Cell Signaling, MA, USA), actin (1:50,000,MP-Biomedicals, UK). 
Densitometry analysis of expression level was performed using EZQuant-Gel software (EZQuant, Israel). 
Phosphorylation of ERK1/2, AKT and mTOR were normalized to total ERK1/2, total AKT or actin respectively. 
For each experiment, activation by Zn2+ (200 µM) was normalized to the response triggered following treatment 
with EDTA (100 µM). The bar graphs represent the averaged response of at least three independent experiments 
performed in triplicates.
For analysis of kinase activation. TAMR or MCF-7 cells, transfected with siRNA were serum starved 
for at least 4 h and then treated with Zn2+ (200 μM, 30 s) or recombinant IGF-1 (100 nM for 30 s, Abcam, UK) or 
EDTA (Ethylenediaminetetraacetic acid used as control at 100 μM, a concentration that does not affect Ca2+ but 
chelates any excess Zn2+, 30 s) in Ca2+-free Ringer’s solution. Cells were then incubated for in Ca2+ free Ringer’s 
solution (20 min for analysis of AKT or mTOR phosphorylation, or 5 min for ERK phosphorylation). In another 
set of experiments, TAMR and MCF-7 cells were incubated for 30 min with the Gq inhibitor YM-254890 (1 μM, 
Astella Pharma, Japan) and then treated as described. Levels of pERK1/2 and pAKT were normalized against the 
total ERK1/2 or AKT protein, respectively.
Real-Time PCR. To determine GPR39 mRNA level, cells were seeded on 60-mm plates and scraped after 
48 h using RNeasy Mini Kit lysis buffer (QIAGEN, Germany). Cell lysates were homogenized using QIAshredder 
and total RNA was purified using RNeasy Mini Kit as described by the manufacturer (QIAGEN, Germany). 1 μg 
RNA was converted to cDNA using qScript cDNA synthesis kit (Quanta Biosciences, MA, USA). 20 ng of the 
cDNA was subjected to real time PCR procedure (Taqman, Applied Biosystems, Thermo Scientific), which was 
done with ABsolute Blue QPCR kit as described by the manufacturer (Thermo Scientific). Primers and probes 
were supplied by (Solaris, Thermo Scientific) sequence for GPR39: forward primer CATCTTCCTGAGGCTGA, 
reverse primer ATGATCCTCCGTCTGGTTG, probe TATGCT GGATGCCCAAC, and for Actin: for-
ward primer TGGAGAAAATCTGGCACCAC, reverse primer GGTCTCAAACATGATCTGG, probe 
ACCGCCAGAAGATGACC.
Proliferation assay/SRB assay for cell density. Sulforhodamine B (SRB) assay was used to assess cell 
proliferation. TAMR and MCF-7 cells were seeded into 24-well plates (60,000 cells per well) and grown in starva-
tion medium: phenol-free RPMI medium containing 1% serum, and 100 µM EDTA, to chelate basal Zn2+ levels, 
for 24 h. MDA-MB-453 cells were seeded into 24-well plates (80,000 cells per well) and supplied with RPMI star-
vation medium with 100 µM EDTA. BT20 cells were seeded into 24-well plates (30,000 cells per well) and supplied 
with EMEM starvation medium with 100 µM EDTA. For daily activation of ZnR/GPR39 activation, cells were 
transferred into Ca2+ free Ringer’s solution and treated with Zn2+ (200 µM, 2 min) or 100 µM EDTA (as control) 
and then returned to the starvation medium for another 24 h. This procedure was repeated during 5–7 consecu-
tive days. Cells were fixed on days 0, 1, 3, 5 and 7 using 10% TCA (trichloroacetic acid) for 1 h at 4 °C. The super-
natant was discarded and plates were washed with deionized water and air-dried, then 300 µl sulforhodamine 
B (SRB 0.4 w/v in 1% acetic acid) was added to each well (10 min at room temperature). The unbound SRB was 
removed by washing with 1% acetic acid and the plates were air-dried. The dye bound to basic amino acids of 
the cell membrane was solubilized with Tris buffer (10 mM, pH 10.5) and the absorption measured at 540 nm 
by ELISA reader (Molecular Devices, CA, USA). Cell number was quantified using a calibration curve, and cell 
proliferation was determined as percentage of the number of cells monitored on day 0 (non-treated, 100%). Each 
bar graph represents an average of at least three independent experiments.
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Invasion. For invasion experiments, growth factor-reduced invasion chambers (Corning) with 8.0 μm PET 
membrane, coated with Matrigel, were used. 50,000 TAMR or MCF-7 cells were seeded in each chamber. At 24 h 
and 48 h cells were treated for 2 min with Zn2+ (200 µM) or EDTA (100 µM), as control, in Ca2+ free Ringer’s 
solution, with or without the Gq inhibitor, YM-254890 (1 μM). After treatment the cells were given starvation 
medium, whereas the well itself contained the regular growth medium of each cell type. At 72 h, matrigel was 
removed using a cotton swab and cells were fixed with 4% PFA. The membranes were removed from the chamber 
using a scalpel blade, and mounted onto a glass microscope slide with a mounting solution containing DAPI 
(Fluoromount-G, Southern Biotech, Thermo Scientific). Cells were counted at 20× magnification in a blind man-
ner. At least three different membranes were counted for each treatment.
Immunofluorescence. To determine GPR39 expression in human breast tumors, a breast cancer tissue 
array was used (Biomax, USA cat # BR1504a). Tissues were de-paraffinized, and after heat-induced antigen 
retrieval (95 °C, 10 min) the tissues were blocked with normal goat serum for 20 min and incubated overnight 
at 4 °C with primary anti-rabbit GPR39 antibody (1:100, Abcam, UK Cat #: AB18859, see negative control in 
Supplementary data 1) and 1 h at room temperature with secondary rabbit Cy2-conjugated antibody (1:100, 
Jackson ImmunoResearch Laboratories, Inc., PA, USA). A cover slide was mounted using a solution containing 
DAPI. The slide was digitalized using the Pannoramic Scanner (3DHISTECH, Budapest, Hungary) and analyzed 
using QuantCenter (3DHISTECH, Budapest, Hungary) using a single threshold parameter for all images. Briefly, 
a person blind to the tissue data determined a threshold value in the stained biopsies, this value of 75 (scale of 
0–254 used on the images) was used for the analysis of the whole slide. The percentage of pixels in each biopsy 
that had a value above this threshold was calculated and biopsies with any percentage above 0 were marked 
as high expression of GPR39. The numbers of positive GPR39- expressing biopsies versus negative expressing 
biopsies was determined, and the tissues were classified as grade 2 or 3 and ER negative or positive expression, 
as done previously73. We then performed a Fisher analysis for the slides that exhibited negative or positive ER, 
separately, and determined the significance of the difference between grade 2 and 3 that were with or without 
GPR39 expression.
Statistical Analysis. Data are expressed as means ± SEM. Each treatment was compared with the control 
or Zn2+ treatment, and statistical significance between the groups was evaluated using the Student’s t-test or 
ANOVA, as marked in figure legends. *p < 0.05.
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